key: cord-0728154-60u3uwnu
authors: DU, Yanbin; Zhou, Nan; ZHA, Wenting; LV, Yuan
title: Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis
date: 2020-12-11
journal: Nutr Metab Cardiovasc Dis
DOI: 10.1016/j.numecd.2020.12.009
sha: 64fcbf24901a204d036247dbf3d90ac802427b2c
doc_id: 728154
cord_uid: 60u3uwnu

Aims As reported, hypertension may play an important role in adverse outcomes of COVID-19, but it still had many confounding factors. The aim of this study was to explore whether hypertension is an independent risk factor for critical COVID-19 and mortality. Data Synthesis The Medline, PubMed, Embase, Web of science databases were systematically searched until November 2020. Combined odds ratios (ORs) with their 95% confidence interval (CIs) were calculated by using random-effect models, and the effect of covariates were analyzed using subgroup analysis and meta-regression analysis. A total of 24 observational studies with 99,918 COVID-19 patients were included in the meta-analysis. The proportions of hypertension in critical COVID-19 were 37%(95%CI: 0.27 −0.47) compared with 18%(95%CI: 0.14 −0.23) of non-critical COVID-19 patients, in those who died were 46%(95%CI: 0.37 −0.55) compared with 22%(95%CI: 0.16 −0.28) of survivors. Pooled results based on the adjusted OR showed that patients with hypertension had a 1.82-fold higher risk for critical COVID-19(aOR: 1.82; 95%CI: 1.19 − 2.77; P=0.005) and a 2.17-fold higher risk for COVID-19 mortality(aOR: 2.17; 95%CI: 1.67 − 2.82; P <0.001). Subgroup analysis results showed that male patients had a higher risk of developing into the critical condition than female(OR: 3.04; 95%CI: 2.06 − 4.49; P < 0.001) and age>60 years was associated with a significantly increased risk of COVID-19 mortality(OR: 3.12; 95%CI: 1.93 − 5.05; P < 0.001). Meta-regression analysis results also showed that age (Coef.= 2.3 × 10 − 2 ,P=0.048) had a significant influence on the association between hypertension and COVID-19 mortality. Conclusions Evidence from this meta-analysis suggested that hypertension was independently associated with a significantly increased risk of critical COVID-19 and in-hospital mortality of COVID-19.

The Coronavirus disease 2019 pandemic presents an unprecedented health crisis to 31 the entire world. As of August 30, the disease has spread to more than 200 countries and territories, 32 including the USA, India, Brazil, Spain, etc., almost 24 million people have been diagnosed with 33 COVID-19 and approximately 836,570 deaths all over the world according to the report of the World 34 Health Organization (WHO) [1] [2] . Therefore, understanding the risk factors associated with 35 COVID-19 susceptibility and severity is crucial to disease control.

Previous studies have shown that common comorbidities (diabetes or cardiovascular, respiratory 37 or kidney disease) were significantly associated with the increased risk of adverse outcomes in 38 patients with . Increasing numbers of reports also linked hypertension to critical 39 COVID-19 and death. Wang et al. [7] reported on 138 COVID-19 patients hospitalised in Wuhan,

China: 31% had hypertension. Of those requiring ICU admission, 58% had hypertension compared 41 with 22% who did not. Zhou et al. [8] reported on 191 hospitalised patients from Wuhan: 30% had 42 hypertension, with 48% of those who died having hypertension compared with 23% of survivors.

However, Yang et al. [9] and Huang et al. [10] reported that hypertension was not more common in 44 those in China with COVID-19 than the general population. So, great differences were shown in the 45 current studies. In addition, the small sample size of patients in these studies further limits its 46 applicability. More importantly, most conclusions were obtained from univariate estimates only.

Several studies have showed that the pooled effects based on the adjusted effect estimates were 48 significantly reduced or even disappeared [11] [12] [13] . So, whether hypertension is an independent risk 49 factor for COVID-19 patients are unclear. 50 Therefore, it is urgently required to clarify the association between hypertension and the adverse 51 outcomes of COVID-19 patients. Compared with the previously published meta-analyses, we herein 52 performed a subgroup analysis based on the adjusted effect estimates to explore whether were discussed and resolved by consensus. For each study, the following information was collected : 84 first author's name, publication year, country, study design, age and sex distribution, sample size, and exposure (0-3points) with a score ranging from 0 to 9 points. We assigned scores of 0-3, 4-6, 93 and 7-9 points for low, moderate, and high quality of the studies, respectively.

The odds ratio (OR) and 95% confidence intervals(CI) were considered as the common 96 measurement of the association between hypertension and the risk of critical COVID-19 and 97 mortality. Heterogeneity among the studies was estimated using the Q and I 2 statistic. For the Q 98 statistics, P < 0.10 indicated statistically significant heterogeneity. And the I 2 values of 25%, 25-99 50%, 50-75%, and >75% were classified as indicating no, small, moderate, and significant 100 heterogeneity, respectively. Pooled ORs were obtained using a fixed-effects model, if I 2 < 50%;

Effect of hypertension on critical COVID-19 was explored from 13 studies (critical=12,522, 139 non-critical=80,174 J o u r n a l P r e -p r o o f 

Preferred reporting items 306 for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

Subtotal (I-squared = 0.0%, p = 0.494)